Good morning. What happens to an organization after it achieves a moonshot? That has been Albert Bourla’s reality, post-COVID. As the CEO of Pfizer, a company he first joined in 1993, Bourla—a ...
Hosted on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
・Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...
SAN FRANCISCO, Jan 12 (Reuters) - Pfizer (PFE.N), opens new tab is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ...
In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s incoming CEO speaks out about the immigration crackdown in the retailer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results